EN  SV

INVESTOR RELATIONS

Welcome to the Fluicell AB Investor Relations page.

On this page you can find annual reports, news, and other information regarding Fluicell.

DOCUMENTS

Currently, we only publish our documents in Swedish.

Finansiella rapporterProspektBolagsordningTeaser

PRESS RELEASES

Subscribe here to press releases.

12/10/2018Fluicells Dynaflow Resolve-chip köps in av prestigefyllda Oxfords universitetNon regulatorisk
10/10/2018Fluicell installerar det första BioPen PRIME-systemet i IsraelNon regulatorisk
29/08/2018Fluicell släpper Biopixlar® produktdesignRegulatorisk
17/08/2018Fluicells delårsrapport för januari-juni 2018Regulatorisk
04/06/2018Fluicell lanserar BioPen på ny marknad genom exklusivt distributionsavtal i IsraelRegulatorisk
01/06/2018Fluicell Tecknar Ytterligare Distributionsavtal för BioPen System i KinaNon regulatorisk
30/05/2018Fluicell: Kommuniké från gårdagens årsstämmaRegulatorisk
24/05/2018Nytt samarbetsavtal stärker produktutvecklingen av Biopixlar™ RetinaRegulatorisk
17/05/2018Meddelande om stabiliseringsåtgärder i Fluicell AB (publ) under perioden 18 april – 17 maj 2018 samt avslut av stabiliseringsåtgärderRegulatorisk
09/05/2018 Årsredovisning 2017Regulatorisk
09/05/2018Delårsrapport 1 januari – 31 mars 2018Regulatorisk
08/05/2018Meddelande om stabiliseringsåtgärder i Fluicell AB (publ) under perioden 27 april – 8 maj 2018Regulatorisk
27/04/2018Kallelse till årsstämma i Fluicell AB (publ)Regulatorisk
26/04/2018Meddelande om stabiliseringsåtgärder i Fluicell AB (publ)Regulatorisk
26/04/2018 Fluicell introducerar BioPen®FLEXRegulatorisk
18/04/2018Handeln av Fluicells aktie på Nasdaq First North inleds i dagRegulatorisk
12/04/2018Kompletterande bolagsinformation inför listning på Nasdaq Stockholm First North
04/04/2018Fluicells nyemission om 32,7 MSEK inför planerad notering på Nasdaq Stockholm First North blev kraftigt övertecknad
23/03/2018Publicerade resultat stärker tekniken bakom Biopixlar™ Retina för att skapa patientrelevanta vävnadsmodeller för läkemedelsutveckling och forskning
16/03/2018Idag inleds teckningstiden i Fluicell AB
15/03/2018Fluicell beslutar om nyemission och offentliggör prospekt inför notering på Nasdaq Stockholm First North
14/03/2018Fluicell AB (PUBL) bokslutskommuniké 2017
03/11/2017Fluicell AB has in-licensed the Dynaflow® Resolve secondary ion channel screening platform technology from Cellectricon AB
24/07/2017Fluicell receives a new patent acceptance for the BioPen system
05/07/2017Biotech uppstickaren Fluicell AB skiner I nyemmision som övertecknades till nära 300%
14/06/2017Fluicell receives green light with a new BioPen patent in the USA

 

MANAGEMENT

  • profile

    Victoire Viannay, Chief Executive Officer

    CEO since 2017.

    Born in 1975.

    Previously the COO of Fluicell AB, Victoire is now the CEO. She holds a PhD in Law from Université Paris II Panthéon/Assas. Former Legal & HR Assistant Manager at Institut Curie, former Project Leader at Chalmers University of Technology, former Chief HR and Legal Officer at PSL Research University, Victoire has more than 10 years of experience in labor laws, human resources and legal management, particularly in the field of scientific research.

    Owns 7,500 shares personally.

  • profile

    Gavin D. M. Jeffries, Chief Technology Officer

    CTO since 2017.

    Born in 1980.

    Currently the CTO of Fluicell AB, Gavin has a PhD in Chemistry from the University of Washington, Seattle. He was Assistant Professor at Chalmers University for 4 years and has published over forty peer reviewed scientific publications, with a total citation count of over a thousand. Entrepreneur/founder of two biotech and optics companies, inventor of multiple patents and technologies, Gavin has a strong background in microfluidics, single-cell analysis and optical platform integration. Gavin has published over forty research articles.

    Owns 46,000 shares personally and 204,000 shares through Jeffries and Associates AB.

  • profile

    Tatsiana Lobovkina, Chief Scientific Officer

    CSO since 2018.

    Born in 1975 .

    Tatsiana is the CSO of Fluicell AB and Assistant Professor at Chalmers University of Technology, Gothenburg. After completing a PhD in chemistry from Chalmers, she completed three years of postdoctoral studies at Stanford University in the USA. With more than 10 years of experience as a research scientist, Tatsiana has a strong background in biophysics and biomimics and has published many scientific publications in international journals.

    Currently doesn't own shares.

  • profile

    Mats Jonasson, Chief Financial Officer

    CFO since 2016.

    Born in 1956.

    Mats is presently the CFO of Fluicell AB via Business Control Partner Norden AB. He studied economy at Gothenburg University, and has, for over 20 years, worked as CFO at companies, such as TiFiC AB and NTEX AB.

    Currently doesn't own shares.

BOARD OF DIRECTORS

  • profile

    Stefan Tilk

    Chairman of the board since 2016.

    Born 1964.

    Stefan Tilk is currently the Vice Chairman and group CEO at NEVS AB. He has a Master’s degree in Engineering Physics from Chalmers University of Technology and studied Business Administration in Barcelona School of Economics. Stefan has extensive experience, leading and developing companies as a CEO, including Geveko AB and Elof Hanson Group. Former Senior Executive Vice President for both Volvo Buses and Volvo Trucks, former Executive Vice President at Coor, Stefan has a strong business development background, skilled in negotiation, business planning, operations management, sales, and international business.
    Owns 30,000 shares through STILK AB.

    Independent in relation to the company and major shareholders.

  • profile

    Owe Orwar

    Board member since 2015.

    Born 1964.

    Owe is the CEO of Oblique Therapeutics and Senior Group Leader at the Karolinska Institute. After completing a PhD in chemistry from Gothenburg University, he completed two years of postdoctoral studies at Stanford University.
    Former Global VP of R&D at Sanofi, former President of R&D at Piramal Healthcare, entrepreneur/founder and inventor of six biotech companies, Owe has over 20 years of experience in the pharma and biotech industry. Holder of more than 75 patents, author of hundreds of research articles, he is a pioneer in the fields of single-cell biology and biophysics with several products on the global market.

    Owns 107,895 shares through Clavis & Vose Invest AB.

  • profile

    Gavin D. M. Jeffries

    Board member since 2012.

    Born in 1980.

    Currently the CTO of Fluicell AB, Gavin has a PhD in Chemistry from the University of Washington, Seattle. He was Assistant Professor at Chalmers University for 4 years and has published over forty peer reviewed scientific publications, with a total citation count of over a thousand. Entrepreneur/founder of two biotech and optics companies, inventor of multiple patents and technologies, Gavin has a strong background in microfluidics, single-cell analysis and optical platform integration. Gavin has published over forty research articles.

    Owns 46,000 shares personally and 204,000 shares through Jeffries and Associates AB.

  • profile

    Daniel T. Chiu

    Board member since 2017.

    Born 1972.

    Education at Harvard University, Stanford University and UC Berkeley.

    Daniel has been Professor of Chemistry and Bioengineering at the University of Washington since 2006. After graduating from Stanford University, he completed postdoctoral research at Harvard University.
    Scientific Founder of multiple Life Sciences/Biomedical companies across Asia, Europe, and U.S.A Member/Chair of numerous advisory and review panels for government and industry, he is a pioneer in the field of single-cell biology with several products on the global market. Daniel has authored more than 200 scientific publications and is the inventor on over 60 issued patents.

    Owns 30,000 shares personally.

    Independent in relation to the company and major shareholders.

  • profile

    Carl Fhager

    Board member since 2017.

    Born in 1975.

    Master of Laws, University of Gothenburg.

    Carl is an experienced and recognized lawyer at MAQS’ Gothenburg office. He has extensive experience of commercial agreements, including ones relating to cooperation, commission, and purchasing, as well as to terms and conditions. He specializes in sports, media, and the entertainment industry in which he has worked for over ten years, in addition to being the sports director of the football club BK Häcken four years. Considering Carl’s dual legal and managerial background, has led him to assist many boards in an advisory manner, or to join them as a member or a chairman.

    Currently doesn't own shares.

    Independent in relation to the company and major shareholders.

CALENDAR

17 August 2018 Q2
21 November 2018 Q3

INFORMATION ABOUT SHAREHOLDERS

Owner Name Ownership Voting Rights
Quiq Distribution Holding AB 529 425 7,07%
Modelio Equity AB (publ) 503 200 6,72%
Carljohan Lagervall AB 428 100 5,72%
ALMI Invest Västsverige AB 409 920 5,48%
Almi Invest AB 300 600 4,02%
Aldo Jesorka 277 830 3,71%
Alar Ainla 263 010 3,51%
Gavin Jeffries, privat och genom bolag 250 000 3,34%
Mangold Fondkommission AB 193 216 2,58%
Danielsson Group AB 188 700 2,52%
Övriga aktieägare 4 142 085 55,32%
Totalt 7 484 970 100,00%

CERTIFIED ADVISOR

Mangold Fondkommission AB tel. +46 8-503-015-50

 

FIRST NORTH

Nasdaq First North is an alternative market, operated by the different exchanges within Nasdaq. It does not have the legal status as an EU-regulated market. Companies at First North are subject to the rules of First North and not the legal requirements for admission to trading on a regulated market. The risk in such an investment may be higher than on the main market. All companies whose shares are traded on First North have a Certified Adviser who monitors that the rules are followed. Nasdaq Stockholm AB approves the application for admission to trading on Nasdaq First North.